Challenges in the value assessment, pricing and funding of targeted combination therapies in oncology
J-Y. Blay and
Health Policy, 2019, vol. 123, issue 12, 1230-1236
The use of targeted combination therapy (TCT) is becoming the standard of care in oncology as cancers are attacked through multiple inhibition mechanisms. TCTs pose a budget challenge to health systems and an economic return challenge for companies developing them.
Keywords: Combination therapy; Health technology assessment; Value assessment; Pricing; Funding; Oncology; Hematology; Targeted combinations (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
Full text for ScienceDirect subscribers only
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:123:y:2019:i:12:p:1230-1236
Access Statistics for this article
Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput
More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Haili He ().